Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ValiRx raises £500,000 to progess cancer trial

ValiRx has one drug, VAL201, going through phase I/II trials
ValiRx raises £500,000 to progess cancer trial
ValiRx has one drug, VAL201, going through phase I/II trials

ValiRx (LON:VAL) has raised £503,000 gross through a placing at 12p per to fund its drug development pipeline.

ValiRx has one drug, VAL201, going through  phase I/II trials, and has made an application to start a second for another cancer treatment, VAL401.

Satu Vainikka, chief executive said: "We are delighted to be able to raise additional funds through this equity placing in a challenging market.

“These funds will enable the company to progress the clinical trial activity that was recently announced."

PhilW.jpg
Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile

ValiRx Plc Timeline

Big Picture
December 02 2016
Newswire
October 13 2016

Related Articles

A graphic of a tumour growing in the body
July 07 2016
Nanobiotix is a late clinical-stage nanomedicine company researching novel approaches to enhance radiotherapy for the local treatment of cancer.
Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln
AZN2.jpg
September 20 2016
The absence of a discount suggests there is a healthy appetite for the equity.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.